The compound has the same kind of lipid-lowering activity that natural thyroid hormone has when it activates receptors in the liver. The prodrug reduces cholesterol and triglyceride levels in mice without side effects.EBSCO_bspChemical & Engineering News...
The use of lipid-lowering agents of several classes has been effective in ameliorating the progression of glomerular damage in a number of different models of glomerulosclerosis. Nevertheless, so far in humans lipid lowering drugs have not been established to have an effect on either the degree of...
Statins form the backbone of lipid-lowering therapy in the prevention of cardiovascular disease. Numerous studies have evaluated the effect of genomics on ... SE Gryn,RA Hegele - 《Clinical Pharmacology & Therapeutics》 被引量: 24发表: 2015年 Pharmacogenetics of Lipid-Lowering Agents: Precision or...
While statins are generally well tolerated, a minority of patients suffers from side effects which diminishes therapy adherence and limits the full potential of risk reduction [3]. Several patients with a proven or perceived intolerance to statins and other established lipid lowering agents use ...
New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines. Clin. Cardiol. 26, III19–24 (2003). 9. Preiss, D. & Sattar, N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin. Endocrinol. (Oxf). 70, ...
et al.: Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents... A.-M. Dupuy,I Carrière,J Scali,... - 《Climacteric》 被引量: 50发表: 2009年 Lipid goal achievement and trends in lipid-lowering th...
Explain the indications for using the various agents in the lipid-lowering therapy family of medications. Review the adverse effect profile of various individuals lipid-lowering therapy agents. Describe interprofessional team strategies for improving care coordination and communication to properly use lipid-...
Statins and fibrates are common lipid-modulating agents and a newer lipid-lowering agent, alirocumab (Praluent), has recently been approved for the treatment of dyslipidemia [2]. Statins are widely used des- pite their potential to cause serious adverse effects such as myopathies and ...
Female patients with type 2 diabetes and CHD were less likely to be treated with lipid-lowering agents than males (38.1% vs. 48.2%, with a disparity of 10.1% in the initiation of LLT between the men and women. Our findings are consistent with those of previous studies in that women with...
Second, selecting lipid-lowering drugs with dual action on lipids and psoriasis promotes personalized treatment (eg, for individuals with dyslipidemia and severe or refractory psoriasis who require adjunctive therapy). Such agents may also be preferred for preventing psoriasis in high-risk individuals (...